Fairvalue-Calculator Fairvalue-Calculator
EN DE

OssDsign AB (OSSD) Fair Value & Analysis

Healthcare · SE · Market cap 494M SEK

Pricekr 4.23
Fair Valuekr 1.43
Upside-66.2%
Quality95/100
Evidence: Low Range kr 0.9400 – kr 1.78

Fair value as of: Jun 25, 2026

Analysis

OssDsign AB (OSSD) currently trades at kr 4.23, while our model-based Fair Value estimate is kr 1.43 — implying the stock looks roughly 66.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in the United States. The company offers OssDsign Catalyst, a nanosynthetic bone graft engages in dual bone formation pathways through fusion mass. OssDsign AB (publ) was founded in 2011 and is headquartered in Uppsala, Sweden.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is OssDsign AB (OSSD) undervalued?
As of Jun 25, 2026, our model estimates a fair value of kr 1.43 versus a price of kr 4.23 — about −66% (overvalued). Model-based estimate, not financial advice.
What is the fair value of OSSD?
Our 21-model fair value for OssDsign AB is kr 1.43 (as of Jun 25, 2026), built from audited fundamentals. The current price is kr 4.23.
What is the quality score of OSSD?
OssDsign AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.